Pancreatic Carcinoma: „Revolutionary“ Extension of Survival Time

german translation / full article

Drug companies and sponsors of drug studies along with their medical partners frequently focus on statistically significant results which in daily life mean little to nothing. In this particular case survival rate after one year was 22 % in the gemcitabine group but 35 % in the combination group. The mean absolute difference, however, was merely 7,2 weeks.

(State: 13.05.2015)

Latest Issue 10/2020

In Focus

  • Challenges of Acute Care
  • Is it Useful to Determine Hormone Levels in Healthy, Symptom-Free Postmenopausal Women?
  • Detecting Victims of Human Trafficking in Family Practice